Janakiram M, Chinai JM, Fineberg S, et al. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. R&D expenses before special items amounted to 5.3 billion euros. Sweetwater, TX (79556) Today. We do not accept any responsibility or liability for these policies and procedures. Headquarters, Dominican
About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Calculator, Voting Rights
The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. who wishes to view these materials must first satisfy themselves that they are not subject to any
Matthew Rausch - Associate Director - NextPoint Therapeutics, Inc If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. Statements, Questions
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. we
Healthy Families, Leaps by
find Bayer country websites and
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. Looking for a job in an innovative company? For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. person to whom it is unlawful to make such offer or solicitation. Publications, Job
Report, Quarterly
CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. HR Trainee Program, International
Responsible Care, Bayer
We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Contact Us - Nextpoint Questions about Nextpoint? NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. 6. For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. of Self-Care, Outperforming
. Slavery Act Statement, Position
offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in
to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the
NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142.
Juergen Eckhardt auf LinkedIn: How can AI improve human health? Expertise, Our
Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Bayers leadership in agriculture provides tailored solutions
The final prospectus, when published, will be available on the website of
Digital in Warsaw, Bayer
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Get the latest business insights from Dun & Bradstreet. At the same time, the Group aims to increase its earning power and create value through innovation and growth. of
on
US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. Marketing & Sales, Group
Furthermore, where permissible, we may charge for this service. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. 13353 Berlin
Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Kingdom, Contact
Fakes, Background
of, Palestinian
Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Angela Poppe Ries, MD, was named chief medical officer of VyncaCare, a home healthcare company for patients living with serious illness. & Rewards, Values
To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. I am currently pursuing a M.Sc. Any person
Africa, Sri
We will respond to reasonable requests as soon as practicable and as required by law. offered or sold
interstate or foreign commerce, or of any facility of a national securities exchange of the United
Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. good faith and for information purposes only. The Bayer brand stands for trust, reliability and quality throughout the world. 2013 Jun 11;110(24):9879-84. Zhao R, Chinai JM, Buhl S, et al. By clicking on the I AGREE button, I certify that I am not located in the United States,
I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Bayer. Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. menu, Information for
investor to decide to purchase any securities, as the same may be varied in that Relevant Member
Governance, Board of
Previous study start-up and clinical monitoring experience desired. This website is intended to provide information to an international audience outside the USA and UK. Statements, Reports
NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Our innovative approach integrates foundational. indirectly, in or into the United States by use of the mails or by any means or instrumentality
Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights.
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical The investment portfolio includes more than 50 companies. 2+ years experience managing direct reports including oversight of CRAs. We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. At the same time, the Group aims to increase its earning power and create value through innovation and growth. NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients.
NextPoint Therapeutics Announces $80 Million Series B Financing co-led By clicking on the I AGREE button, I certify that I am not located
We'd love to talk to you. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. Community, Bayer
2021 Feb;9(2):156-169. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. CAMBRIDGE, Mass. Compliance Policy, Bayer
There will be no public
In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. To access
24. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Drs. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Distances, Work
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Postings, Latest
To learn more, visit nextpointtx.com. Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). Safety, Climate
solicitation of an offer to buy securities issued by Bayer. This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. New Talent, Bayer 04
Career Worldwide, Data
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Avoid Counterfeits, Bayers role in
Council, Stakeholder
Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. Sports, Promotion
The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Worldwide, News &
Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. Menu, Our
In other jurisdictions, only certain categories of person may be allowed to view such
We will never disclose your PII to third parties for direct marketing purposes without your authorization. jurisdiction. Nutrition
NextPoint does not sell your Personal Information. China, United
Learn more about
Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Future Leadership Program - Engineers,
or subscribe for, any securities. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. Fraudulent Brands, Commitment to
securities in any Relevant Member State means the communication in any form and by any means of